trial summary · NCT07170293
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
An Exploratory, Prospective, Single Arm, Open Label, Single Center, Basket, Phase II Clinical Study of Tunlametinib (HL-085) in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Trial record from the TrialBase DB dataset, status RECRUITING, condition Solid Cancers, sponsored by Tianjin Medical University Second Hospital. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This study is a single cohort, open label exploratory clinical trial aimed at observing and evaluating the efficacy and safety of Tunlametinib (HL-085) in the treatment of refractory solid tumors with advanced metastatic non melanoma. It is expected that the ORR of Tunlametinib (HL-085) treatment can reach 20%. According to the literature results, the experimental group rate is 0.2 and the target value rate is 0.02. If the bilateral alpha is 0.05 and the beta is 0.2, the sample size is calculated as 12 cases in the experimental group. Considering a 20% dropout rate, a total of 15 cases are required.
Source record: https://clinicaltrials.gov/study/NCT07170293
Facts
| registry id | NCT07170293 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Solid Cancers |
| sponsor | Tianjin Medical University Second Hospital |
| sponsor class | OTHER |
| enrollment | 15 |
| start date | 2027-08-31 |
| primary completion | 2027-09-30 |
| completion | 2027-09-30 |
| results posted | not reported |
Conditions
- Solid Cancers
Interventions
- Tunlametinib
Countries
- China
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.